Literature DB >> 17436849

Factors influencing the loss of beta-cell mass in islet transplantation.

Juliet A Emamaullee1, A M James Shapiro.   

Abstract

Recent advances in clinical islet transplantation have clearly demonstrated that this procedure can provide excellent glycemic control and often insulin independence in a population of patients with type 1 diabetes. A key limitation in the widespread application of clinical islet transplantation is the requirement of 10,000 islet equivalents/kg in most recipients, generally derived from two or more cadaveric donors. It has been determined that a majority of the transplanted islets fail to engraft and become fully functional. In this review article, the factors that contribute to this early loss of islets following transplantation are discussed in depth.

Entities:  

Mesh:

Year:  2007        PMID: 17436849

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  45 in total

1.  Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine models.

Authors:  Romie F Gibly; Xiaomin Zhang; Melanie L Graham; Bernhard J Hering; Dixon B Kaufman; William L Lowe; Lonnie D Shea
Journal:  Biomaterials       Date:  2011-09-28       Impact factor: 12.479

2.  PEG-maleimide hydrogels for protein and cell delivery in regenerative medicine.

Authors:  Andrés J García
Journal:  Ann Biomed Eng       Date:  2013-07-24       Impact factor: 3.934

3.  PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.

Authors:  John G Graham; Xiaomin Zhang; Ashley Goodman; Kathryn Pothoven; Josetta Houlihan; Shusen Wang; R Michael Gower; Xunrong Luo; Lonnie D Shea
Journal:  Tissue Eng Part A       Date:  2013-04-03       Impact factor: 3.845

4.  Development and Validation of Noninvasive Magnetic Resonance Relaxometry for the In Vivo Assessment of Tissue-Engineered Graft Oxygenation.

Authors:  Samuel A Einstein; Bradley P Weegman; Meri T Firpo; Klearchos K Papas; Michael Garwood
Journal:  Tissue Eng Part C Methods       Date:  2016-11       Impact factor: 3.056

5.  In vivo noninvasive monitoring of dissolved oxygen concentration within an implanted tissue-engineered pancreatic construct.

Authors:  Fernie Goh; Athanassios Sambanis
Journal:  Tissue Eng Part C Methods       Date:  2011-05-25       Impact factor: 3.056

6.  Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization.

Authors:  Edward A Phelps; Kellie L Templeman; Peter M Thulé; Andrés J García
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

7.  Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival.

Authors:  Juliet A Emamaullee; Joy Davis; Rena Pawlick; Christian Toso; Shaheed Merani; Sui-Xiong Cai; Ben Tseng; A M James Shapiro
Journal:  Diabetes       Date:  2010-03-23       Impact factor: 9.461

8.  Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  J Diabetes Sci Technol       Date:  2008-09

9.  Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies.

Authors:  Seung-Hee Lee; Ergeng Hao; Alexei Y Savinov; Ifat Geron; Alex Y Strongin; Pamela Itkin-Ansari
Journal:  Transplantation       Date:  2009-04-15       Impact factor: 4.939

Review 10.  Slow and steady is the key to beta-cell replication.

Authors:  Kristen Brennand; Doug Melton
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.